Sign In
Buy HCM
$11.13
+0.360 (+3.34%)
At Close: Jul 31, 2026
HUTCHMED (China) Limited (HCM) Q2 2026 Earnings Call Transcript
03:43pm, Thursday, 30'th Jul 2026
HUTCHMED (China) Limited (HCM) Q2 2026 Earnings Call Transcript
HUTCHMED H1 Earnings Call Highlights
01:08pm, Thursday, 30'th Jul 2026
HUTCHMED NASDAQ: HCM reported first-half 2026 oncology revenue of $162 million, including $121 million in product revenue, as growth in China and expanding international sales of FRUZAQLA supported re
Study substantially exceeded enrollment target of 500 patients Topline results anticipated in Q1 2027 THE WOODLANDS, Texas, July 27, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXR
Hutchmed: Bullish On Their Commercial Prospects And Pipeline Catalysts
08:30am, Sunday, 19'th Jul 2026
Hutchmed basically combines a growing oncology franchise with late-stage immunology assets and an early ATTC pipeline. Their Fruzaqla international rollout and improving China execution could also hel
AI Solution Providers Shift From AI Features to AI-Enabled Execution
11:00am, Tuesday, 14'th Jul 2026
[url="]The Hackett Group, Inc.[/url] (NASDAQ: HCKT), an ROI-led AI transformation firm, today released new research examining how artificial intelligence (AI)
HUTCHMED Announces NMPA Approval for ORPATHYS® for the treatment of Gastric Cancer Patients with MET Amplification
04:30am, Thursday, 02'nd Jul 2026
First selective MET inhibitor approved for patients with MET-amplified advanced gastric cancer or gastroesophageal junction adenocarcinoma in China First selective MET inhibitor approved for patients
HUTCHMED to Announce 2026 Half-Year Financial Results
04:30am, Tuesday, 30'th Jun 2026
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., June 30, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX:13) will announce its interim results for the six mont
Buy These 3 HCM Software Solution Stocks to Tap Short-Term Potential
09:30am, Friday, 26'th Jun 2026
AI-driven hiring and HR automation are reshaping HCM software, with three companies, namely, PAYC, PCTY and FA standing out for short-term upside.
Syndio Acquires Embrace.ai
12:30pm, Tuesday, 23'rd Jun 2026
SEATTLE--(BUSINESS WIRE)--Syndio, the Decision Intelligence for Pay company, today announced the acquisition of Embrace.ai, an agentic AI company built to deploy AI-driven automation across business w
LAS VEGAS, June 16, 2026 (GLOBE NEWSWIRE) -- Connect For Partners -- isolved ® today unveiled the first autonomous AI agents built to own HR, payroll and benefits outcomes, and launched general avail
– No relationship observed between EDG-7500 exposure and LVEF; no LVEF reductions below 50% – – Consistent and clinically meaningful improvements observed in echocardiogram parameters, biomarker
isolved Honors Top-Performing Partners at Annual Connect for Partners Event
08:30pm, Monday, 15'th Jun 2026
LAS VEGAS, June 15, 2026 (GLOBE NEWSWIRE) -- Connect for Partners – isolved®, a provider of human capital management (HCM) solutions that help organizations recruit, retain and elevate their workfo
LAS VEGAS, June 15, 2026 (GLOBE NEWSWIRE) -- Connect For Partners – isolved, a provider of human capital management (HCM) solutions that help organizations recruit, retain and elevate their workfor
Paychex Recognized as a Top WorkTech Company by TIME
09:30am, Monday, 15'th Jun 2026
Paychex named a leading HCM provider to TIME's America's Top WorkTech Companies 2026 List List identifies the most impactful and financially strong companies that have established themselves as leader
HUTCHMED Highlights Sovleplenib ESLIM-02 Phase III Data in Warm Antibody Autoimmune Hemolytic Anemia Presented at EHA 2026 Congress
08:00pm, Thursday, 11'th Jun 2026
— Sovleplenib demonstrated rapid and durable hemoglobin response with favorable safety profile — —The ESLIM-02 study underscores sovleplenib's potential to address critical unmet needs in a trea
